Beijing Tong Ren Tang Chinese Medicine Company Limited
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine to wholesalers and individuals. It operates through three segments: Hong Kong, Mainland China, and Overseas. The company offers Chinese medical consultation and treatment services. It also operates retail outlets in H… Read more
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) - Net Assets
Latest net assets as of June 2025: $4.22 Billion USD
Based on the latest financial reports, Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) has net assets worth $4.22 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.53 Billion) and total liabilities ($312.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.22 Billion |
| % of Total Assets | 93.11% |
| Annual Growth Rate | 9.26% |
| 5-Year Change | 35.39% |
| 10-Year Change | N/A |
| Growth Volatility | 7.47 |
Beijing Tong Ren Tang Chinese Medicine Company Limited - Net Assets Trend (2015–2024)
This chart illustrates how Beijing Tong Ren Tang Chinese Medicine Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Tong Ren Tang Chinese Medicine Company Limited (2015–2024)
The table below shows the annual net assets of Beijing Tong Ren Tang Chinese Medicine Company Limited from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $546.43 Million | +6.15% |
| 2023-12-31 | $514.77 Million | +7.56% |
| 2022-12-31 | $478.60 Million | +5.45% |
| 2021-12-31 | $453.87 Million | +12.45% |
| 2020-12-31 | $403.61 Million | +13.71% |
| 2019-12-31 | $354.94 Million | -8.11% |
| 2018-12-31 | $386.27 Million | +15.77% |
| 2017-12-31 | $333.64 Million | +16.14% |
| 2016-12-31 | $287.27 Million | +16.63% |
| 2015-12-31 | $246.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Tong Ren Tang Chinese Medicine Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 259.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $411.13 Million | 78.40% |
| Common Stock | $120.80 Million | 23.04% |
| Total Equity | $524.42 Million | 100.00% |
Beijing Tong Ren Tang Chinese Medicine Company Limited Competitors by Market Cap
The table below lists competitors of Beijing Tong Ren Tang Chinese Medicine Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Westwing Group AG
F:WEW
|
$153.82 Million |
|
Xuchang Ketop Testing Research Ins
SHE:003008
|
$153.91 Million |
|
Designer Brands Inc
NYSE:DBI
|
$153.96 Million |
|
Ohio Valley Banc Corp
NASDAQ:OVBC
|
$153.97 Million |
|
308430
KQ:308430
|
$153.64 Million |
|
Guangdong Yantang Dairy Co Ltd
SHE:002732
|
$153.64 Million |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
$153.59 Million |
|
Washington Real Estate Investment Trust
F:WRI
|
$153.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Tong Ren Tang Chinese Medicine Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 495,029,659 to 524,417,324, a change of 29,387,665 (5.9%).
- Net income of 64,375,773 contributed positively to equity growth.
- Dividend payments of 276,243,000 reduced retained earnings.
- Other comprehensive income increased equity by 3,849,221.
- Other factors increased equity by 237,405,671.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $64.38 Million | +12.28% |
| Dividends Paid | $276.24 Million | -52.68% |
| Other Comprehensive Income | $3.85 Million | +0.73% |
| Other Changes | $237.41 Million | +45.27% |
| Total Change | $- | 5.94% |
Book Value vs Market Value Analysis
This analysis compares Beijing Tong Ren Tang Chinese Medicine Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.31x to 1.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.28 | $0.65 | x |
| 2016-12-31 | $0.33 | $0.65 | x |
| 2017-12-31 | $0.38 | $0.65 | x |
| 2018-12-31 | $0.44 | $0.65 | x |
| 2019-12-31 | $0.41 | $0.65 | x |
| 2020-12-31 | $0.46 | $0.65 | x |
| 2021-12-31 | $0.52 | $0.65 | x |
| 2022-12-31 | $0.55 | $0.65 | x |
| 2023-12-31 | $0.59 | $0.65 | x |
| 2024-12-31 | $0.63 | $0.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Tong Ren Tang Chinese Medicine Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.28%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.99%
- • Asset Turnover: 2.75x
- • Equity Multiplier: 1.12x
- Recent ROE (12.28%) is below the historical average (27.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 19.51% | 36.50% | 0.48x | 1.12x | $22.28 Million |
| 2016 | 19.80% | 38.76% | 0.46x | 1.11x | $26.84 Million |
| 2017 | 19.65% | 38.70% | 0.46x | 1.11x | $30.79 Million |
| 2018 | 19.99% | 38.36% | 0.48x | 1.09x | $37.06 Million |
| 2019 | 20.91% | 38.82% | 0.46x | 1.18x | $37.24 Million |
| 2020 | 17.98% | 41.24% | 0.38x | 1.14x | $31.04 Million |
| 2021 | 17.78% | 39.06% | 0.40x | 1.13x | $34.11 Million |
| 2022 | 17.92% | 37.31% | 0.41x | 1.18x | $36.54 Million |
| 2023 | 109.16% | 276.71% | 0.34x | 1.15x | $490.89 Million |
| 2024 | 12.28% | 3.99% | 2.75x | 1.12x | $11.93 Million |
Industry Comparison
This section compares Beijing Tong Ren Tang Chinese Medicine Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) | $4.22 Billion | 19.51% | 0.07x | $153.70 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |